The therapy has the potential to treat neurological and oncological conditions
News
Research provides hope for patients with neurodegenerative disease
Findings highlight a potential new drug candidate that may delay disease progression
Sequana announces results from study of direct sodium removal
All ten patients involved in the research effectively and rapidly eliminated persistent congestion
Norfolk and Norwich University Hospitals establishes therapy for ovarian cancer patients
Procedure is carried out following the completion of surgery to remove all visible disease
Lindis biotech presents encouraging data from bladder cancer trial
Data revealed that 100% of patients achieved a complete remission with no recurrence
Priothera reveals positive mocravimod data
Therapy is well-tolerated in allogeneic haematopoietic cell transplantation (HCT) patients
Stada and Xbrane gain EU approval for biosimilar Ximluci
Partnership combines Xbrane’s protein-expression system with Stada’s management teams
Bristol Myers Squibb opens 125-acre biologics campus in Dublin
Facility also includes a cell culture suite, quality control laboratories and technology labs
Brainomix and Visionable announce AI partnership
Link up will take on bottlenecks in time-sensitive stroke care pathway across the UK
EnteroBiotix announces partnership with Imperial College London
Collaboration includes a phase 2 clinical trial using microbiome therapeutics funded by the MRC
MHRA extends Cosentyx licence for paediatric arthritis
Data demonstrates that secukinumab shows a significantly longer time to flare versus placebo
Positive results for Ipsen’s metastatic pancreatic cancer treatment
Onivyde regimen demonstrated statistically significant improvement in overall survival
EIT Health’s Venture Centre of Excellence in link-up with ProductLife
ProductLife becomes partner in upholding regulatory and compliance across life sciences
SMC expands guidance for Lokelma to emergency care settings
New access to treatment involves adult patients with hyperkalaemia across Scotland
Rivus presents results from trial evaluating controlled metabolic accelerator
HU6 data demonstrates significant selective weight loss across all body compartments
